Driehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 594,015 shares of the company’s stock, valued at approximately $2,014,000. Driehaus Capital Management LLC owned 0.40% of Xeris Biopharma at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. NewEdge Advisors LLC bought a new position in Xeris Biopharma during the 4th quarter worth $34,000. R Squared Ltd bought a new position in shares of Xeris Biopharma in the fourth quarter worth $42,000. Cibc World Markets Corp acquired a new position in Xeris Biopharma in the fourth quarter valued at about $44,000. Raymond James Financial Inc. bought a new stake in Xeris Biopharma during the fourth quarter worth about $45,000. Finally, Aquatic Capital Management LLC acquired a new stake in Xeris Biopharma during the fourth quarter worth about $50,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Trading Down 2.5 %

Xeris Biopharma stock opened at $5.03 on Friday. The stock has a 50-day moving average price of $4.66 and a two-hundred day moving average price of $3.85. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.73 and a 12 month high of $6.07. The company has a market capitalization of $786.62 million, a PE ratio of -11.18 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. As a group, analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the firm’s stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. This trade represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.47% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on XERS. Oppenheimer boosted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Leerink Partners boosted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Craig Hallum increased their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.